Abstract:Background: The purpose of the present study was to investigate the use of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor(VEGF) levels to monitor the treatment response to transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Methods: A total of 41 consecutive HCC patients underwent TACE were enrolled into this study. The serum levels of HIF-1 alpha and VEGF were measured using enzyme-linked immunosorbent assays (ELISAs) 1 day before, and 1, 7 and 28 days after TACE therapy. The overall tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors criteria. Patients with a complete response or partial response comprised the responding group, whereas thaw with stable disease or progressive disease comprised the non-responding group. The differences in serum HIF-1 alpha and VEGF levels before and after TACE therapy were subjected to analysis of nonparametric test, while correlations between serum HIF-1 alpha and VEGF levels were examined using Pearson's correlation analysis. Receiver-operating characteristic (ROC) curve was applied to analyze the evaluation value of factors for the response of TACE on the treatment of HCC. P<0.05 was considered statistically significant. Results: In the present study, the serum levels of HIF-1 alpha correlated positively with the serum levels of VEGF 1 day before TACE (r = 0.546, P = 0.000). The levels of HIF-1 alpha and VEGF 1 day before, and 1, 7 and 28 days after TACE were significantly different, respectively (chi(2)= 90.688, P = 0.000 and chi(2)= 45.585 , P = 0.000). The levels of the HIF-1 alpha and VEGF increased markedly on day 1 and 7 after TACE and recovered to the pre-TACE level on day 28 after TACE. The levels of serum VEGF in responder group 28 days after TACE were significantly lower than those in non-responder group (Z = 2.774, P = 0.006), but the difference of HIF-1 alpha levels between the two groups was not significant (Z = 1.905, P = 0.057). ROC curve analysis indicated that the sensitivity and specificity were 76.9% and 78.6%, when the threshold value was set at VEGF = 254.5 pg/ml, for predicting the response of TACE in patients with HCC; the corresponding area under the curve (AUC) was 0.772, respectively. Conclusions: The levels of both HIF-1 alpha and VEGF in patients with HCC after TACE exhibit dynamic changes. However, HIF-1 alpha and VEGF may be insufficient for predicting tumor response to TACE treatment.

Impact of serum nm23-H1 level on the prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization treatment

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Correlation of nm23 and E-cadherin protein expression with recurrence and metastasis after liver transplantation for hepatocellular carcinoma

Expressions of Nucleoside Diphosphate Kinase (nm23) in Tumor Tissues Are Related with Metastasis and Length of Survival of Patients with Hepatocellular Carcinoma

Impact of hepatectomy and postoperative adjuvant transarterial chemoembolization on serum tumor markers and prognosis in intermediate-stage hepatocellular carcinoma

Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization

Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.

The level of serum VCAM-1 in patients with primary hepatocellular carcinoma and its clinical significance

Expression of PCNA and Nm23-H1/ndpk in Hepatocellular Carcinoma Following Transcatheter Arterial Chemoembolization Therapy

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Impact of Serum Vascular Endothelial Growth Factor on Prognosis in Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization

Significance of the Changes in Serum Soluble Intercellular Adhesion Molecule-1 in Patients with Hepatocellular Carcinoma Before and after TACE

Prognostic Evaluation Function of Serum Alpha-Fetoprotein for Primary Hepatocellular Carcinoma in Patients Treated with TACE and RFA

Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization

HIF-1α and VEGF Levels for Monitoring Hepatocellular Carcinoma Treatment Response to Transcatheter Arterial Chemoembolization

The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization

Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma

Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C-related Hepatocellular Carcinoma Among Egyptians: A Prospective Study

Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization